Abstract
Genetic studies of Alzheimer disease (AD) have prioritized variants in genes related to the amyloid cascade, lipid metabolism, and neuroimmune modulation. However, the cell-specific effect of variants in these genes is not fully understood. Here, we perform single-nucleus RNA-sequencing (snRNA-seq) on nearly 300,000 nuclei from the parietal cortex of AD autosomal dominant (APP and PSEN1) and risk-modifying variant (APOE, TREM2 and MS4A) carriers. Within individual cell types, we capture genes commonly dysregulated across variant groups. However, specific transcriptional states are more prevalent within variant carriers. TREM2 oligodendrocytes show a dysregulated autophagy-lysosomal pathway, MS4A microglia have dysregulated complement cascade genes, and APOEε4 inhibitory neurons display signs of ferroptosis. All cell types have enriched states in autosomal dominant carriers. We leverage differential expression and single-nucleus ATAC-seq to map GWAS signals to effector cell types including the NCK2 signal to neurons in addition to the initially proposed microglia. Overall, our results provide insights into the transcriptional diversity resulting from AD genetic architecture and cellular heterogeneity. The data can be explored on the online browser (http://web.hararilab.org/SNARE/).
Original language | English |
---|---|
Article number | 2314 |
Journal | Nature communications |
Volume | 14 |
Issue number | 1 |
DOIs | |
State | Published - Dec 2023 |
Fingerprint
Dive into the research topics of 'Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Nature communications, Vol. 14, No. 1, 2314, 12.2023.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers
AU - Dominantly Inherited Alzheimer Network (DIAN)
AU - Brase, Logan
AU - You, Shih Feng
AU - D’Oliveira Albanus, Ricardo
AU - Del-Aguila, Jorge L.
AU - Dai, Yaoyi
AU - Novotny, Brenna C.
AU - Soriano-Tarraga, Carolina
AU - Dykstra, Taitea
AU - Fernandez, Maria Victoria
AU - Budde, John P.
AU - Bergmann, Kristy
AU - Morris, John C.
AU - Bateman, Randall J.
AU - Perrin, Richard J.
AU - McDade, Eric
AU - Xiong, Chengjie
AU - Goate, Alison M.
AU - Farlow, Martin
AU - Sutherland, Greg T.
AU - Kipnis, Jonathan
AU - Karch, Celeste M.
AU - Benitez, Bruno A.
AU - Harari, Oscar
N1 - Funding Information: Doctors Celeste M. Karch, Bruno A. Benitez, and Oscar Harari contributed equally to this work as co-senior authors. Data collection and sharing for this project were supported by The Dominantly Inherited Alzheimer Network (DIAN, U19AG032438), funded by the National Institute on Aging (NIA), the Alzheimer’s Association (SG-20-690363-DIAN), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Spanish Institute of Health Carlos III (ISCIII), Canadian Institutes of Health Research (CIHR), Canadian Consortium of Neurodegeneration and Aging, Brain Canada Foundation, and Fonds de Recherche du Québec – Santé. DIAN Study investigators have reviewed this manuscript for scientific content and consistency of data interpretation with previous DIAN Study publications. We acknowledge the altruism of the participants and their families and the contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study. The results published here are partly based on data obtained from the AD Knowledge Portal ( https://adknowledgeportal.org ). Study data were provided by the Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917 (MAP), R01AG30146, R01AG36042 (5hC methylation, ATAC-seq), RC2AG036547 (H3K9Ac), R01AG36836 (RNAseq), R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus RNAseq), U01AG32984 (genomic and whole exome sequencing), U01AG46152 (ROSMAP AMP-AD, targeted proteomics), U01AG46161(TMT proteomics), U01AG61356 (whole genome sequencing, targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health (ROSMAP), and the Translational Genomics Research Institute (genomic). Additional phenotypic data can be requested at www.radc.rush.edu . This work was possible thanks to the following governmental grants from the National Institute of Health: NIA R01AG057777 (O.H.), R56AG067764 (O.H.), U01AG072464 (O.H. and C.M.K.), R01AG074012 (O.H.) P30AG066444 (JCM), P01AGO26276 (JCM), U19AG032438 (RJB), P01AG003991 (J.C.M.), NINDS R01NS118146 (B.A.B.), R21NS127211 (B.A.B.), RF1AG071706 (B.A.B.), RFNS110809 (C.M.K.), R01AG062734 (C.M.K.), NIA T32AG058518 (L.B.), the BrightFocus Foundation (C.M.K.), and the Chan Zuckerberg Initiative (C.M.K.). O.H. is an Archer Foundation Research Scientist. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders and the Departments of Neurology and Psychiatry at Washington University School of Medicine. The funders of the study had no role in the collection, analysis, or interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. Fig was created with BioRender.com Funding Information: Doctors Celeste M. Karch, Bruno A. Benitez, and Oscar Harari contributed equally to this work as co-senior authors. Data collection and sharing for this project were supported by The Dominantly Inherited Alzheimer Network (DIAN, U19AG032438), funded by the National Institute on Aging (NIA), the Alzheimer’s Association (SG-20-690363-DIAN), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Spanish Institute of Health Carlos III (ISCIII), Canadian Institutes of Health Research (CIHR), Canadian Consortium of Neurodegeneration and Aging, Brain Canada Foundation, and Fonds de Recherche du Québec – Santé. DIAN Study investigators have reviewed this manuscript for scientific content and consistency of data interpretation with previous DIAN Study publications. We acknowledge the altruism of the participants and their families and the contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study. The results published here are partly based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org). Study data were provided by the Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917 (MAP), R01AG30146, R01AG36042 (5hC methylation, ATAC-seq), RC2AG036547 (H3K9Ac), R01AG36836 (RNAseq), R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus RNAseq), U01AG32984 (genomic and whole exome sequencing), U01AG46152 (ROSMAP AMP-AD, targeted proteomics), U01AG46161(TMT proteomics), U01AG61356 (whole genome sequencing, targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health (ROSMAP), and the Translational Genomics Research Institute (genomic). Additional phenotypic data can be requested at www.radc.rush.edu. This work was possible thanks to the following governmental grants from the National Institute of Health: NIA R01AG057777 (O.H.), R56AG067764 (O.H.), U01AG072464 (O.H. and C.M.K.), R01AG074012 (O.H.) P30AG066444 (JCM), P01AGO26276 (JCM), U19AG032438 (RJB), P01AG003991 (J.C.M.), NINDS R01NS118146 (B.A.B.), R21NS127211 (B.A.B.), RF1AG071706 (B.A.B.), RFNS110809 (C.M.K.), R01AG062734 (C.M.K.), NIA T32AG058518 (L.B.), the BrightFocus Foundation (C.M.K.), and the Chan Zuckerberg Initiative (C.M.K.). O.H. is an Archer Foundation Research Scientist. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders and the Departments of Neurology and Psychiatry at Washington University School of Medicine. The funders of the study had no role in the collection, analysis, or interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. Fig 1a was created with BioRender.com Publisher Copyright: © 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Genetic studies of Alzheimer disease (AD) have prioritized variants in genes related to the amyloid cascade, lipid metabolism, and neuroimmune modulation. However, the cell-specific effect of variants in these genes is not fully understood. Here, we perform single-nucleus RNA-sequencing (snRNA-seq) on nearly 300,000 nuclei from the parietal cortex of AD autosomal dominant (APP and PSEN1) and risk-modifying variant (APOE, TREM2 and MS4A) carriers. Within individual cell types, we capture genes commonly dysregulated across variant groups. However, specific transcriptional states are more prevalent within variant carriers. TREM2 oligodendrocytes show a dysregulated autophagy-lysosomal pathway, MS4A microglia have dysregulated complement cascade genes, and APOEε4 inhibitory neurons display signs of ferroptosis. All cell types have enriched states in autosomal dominant carriers. We leverage differential expression and single-nucleus ATAC-seq to map GWAS signals to effector cell types including the NCK2 signal to neurons in addition to the initially proposed microglia. Overall, our results provide insights into the transcriptional diversity resulting from AD genetic architecture and cellular heterogeneity. The data can be explored on the online browser (http://web.hararilab.org/SNARE/).
AB - Genetic studies of Alzheimer disease (AD) have prioritized variants in genes related to the amyloid cascade, lipid metabolism, and neuroimmune modulation. However, the cell-specific effect of variants in these genes is not fully understood. Here, we perform single-nucleus RNA-sequencing (snRNA-seq) on nearly 300,000 nuclei from the parietal cortex of AD autosomal dominant (APP and PSEN1) and risk-modifying variant (APOE, TREM2 and MS4A) carriers. Within individual cell types, we capture genes commonly dysregulated across variant groups. However, specific transcriptional states are more prevalent within variant carriers. TREM2 oligodendrocytes show a dysregulated autophagy-lysosomal pathway, MS4A microglia have dysregulated complement cascade genes, and APOEε4 inhibitory neurons display signs of ferroptosis. All cell types have enriched states in autosomal dominant carriers. We leverage differential expression and single-nucleus ATAC-seq to map GWAS signals to effector cell types including the NCK2 signal to neurons in addition to the initially proposed microglia. Overall, our results provide insights into the transcriptional diversity resulting from AD genetic architecture and cellular heterogeneity. The data can be explored on the online browser (http://web.hararilab.org/SNARE/).
UR - http://www.scopus.com/inward/record.url?scp=85153549541&partnerID=8YFLogxK
U2 - 10.1038/s41467-023-37437-5
DO - 10.1038/s41467-023-37437-5
M3 - Article
C2 - 37085492
AN - SCOPUS:85153549541
SN - 2041-1723
VL - 14
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 2314
ER -